Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"C4X Discovery","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$433.2 million","upfrontCash":"$7.3 million","newsHeadline":"Up to \u20ac414 Million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A Inhibitor Programme","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$402.0 million","upfrontCash":"$2.0 million","newsHeadline":"C4XD Agreement with AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior for \u00a315.95m","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by C4X Discovery

    Menu

    C4X Discovery

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              C4X Discovery

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior for £15.95m

              Details:

              Through the divestment, Indivior gains the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, INDV-2000 (C4X_3256) for substance use disorder.

              Lead Product(s): C4X_3256

              Therapeutic Area: Psychiatry/Psychology Product Name: INDV-2000

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Indivior

              Deal Size: $20.4 million Upfront Cash: Undisclosed

              Deal Type: Divestment August 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              C4X Discovery

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              C4XD Agreement with AstraZeneca

              Details:

              C4XD signs licence agreement with AstraZeneca for the development and commercialisation of NRF2 Activator programme. NRF2 is an important natural regulator, controlling the expression of antioxidant genes, and it plays a key role in cellular defense against external insults.

              Lead Product(s): C4X_6665

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C4X_6665

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: $402.0 million Upfront Cash: $2.0 million

              Deal Type: Agreement November 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              C4X Discovery

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Up to €414 Million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A Inhibitor Programme

              Details:

              Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of inflammatory diseases. The IL-17 family of cytokines are inducers of inflammation in variety of autoimmune diseases including psoriasis, psoriatic arthritis & ankylosing spondylitis.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: $433.2 million Upfront Cash: $7.3 million

              Deal Type: Licensing Agreement April 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY